Inmed Pharmaceuticals Inc (INM)

$2.30 -0.02 (-0.86%)
Market Cap 4.65M
Revenue (ttm) 4.60M
Net Income (ttm) -7.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -166.96%
Debt to Equity Ratio 0.00
Volume 40,223
Avg Vol 2,367,254
Day's Range N/A - N/A
Shares Out 2.00M
Stochastic %K 67%
Beta 0.29
Analysts Strong Buy
Price Target $45.00

Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. It operates through two segments: InMed Pharma and BayMedica Commercial. The InMed Pharma segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products inc...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 604 669 7207
Fax: 778 945 6800
Address:
885 West Georgia Street, Suite 1445, Vancouver, Canada
MdcRaven13
MdcRaven13 Aug. 18 at 2:06 PM
$INM I imagine this one will heat up the higher that tilray and sundial go
0 · Reply
KKEE122
KKEE122 Aug. 18 at 3:09 AM
$INM According to my reading of the chart, I see that it is ready to launch $5 or more. I have informed you. Do not say that I have not informed you.
0 · Reply
SmartBetting
SmartBetting Aug. 14 at 2:20 PM
$INM showtime is coming. goodluck.
0 · Reply
Space0
Space0 Aug. 14 at 1:15 PM
$INM smart money vibes right here 🚀 He clearly sees the massive upside in $INM — and I’m with him on this one
0 · Reply
aw20
aw20 Aug. 11 at 9:55 AM
$INM when this one runs, it runs hard 👀 loaded the dip for the next good news
0 · Reply
Space0
Space0 Aug. 11 at 9:07 AM
$INM unusual strength without headlines — the tape might be telling us that good news is just around the corner
0 · Reply
SuperFugazi
SuperFugazi Aug. 11 at 6:51 AM
$INM idiot
0 · Reply
Lolonaktie
Lolonaktie Aug. 7 at 8:53 AM
$INM It's at rock bottom. We need to push the stock up.
0 · Reply
aw20
aw20 Aug. 6 at 3:20 PM
$INM loaded again at 2.27. Expecting news soon 👀 NFA
0 · Reply
april1688
april1688 Aug. 6 at 1:41 PM
$INM how is inm now?
0 · Reply
Latest News on INM
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Jul 28, 2025, 7:00 AM EDT - 21 days ago

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jun 27, 2025, 7:00 AM EDT - 7 weeks ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 25, 2025, 8:00 AM EDT - 7 weeks ago

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 24, 2025, 7:00 AM EDT - 7 weeks ago

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

Jun 13, 2025, 4:30 PM EDT - 2 months ago

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 12, 2025, 6:00 PM EDT - 3 months ago

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 6:54 PM EST - 6 months ago

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Feb 3, 2025, 7:30 AM EST - 7 months ago

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Jan 22, 2025, 7:30 AM EST - 7 months ago

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Jan 21, 2025, 7:30 AM EST - 7 months ago

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

InMed Announces Results of 2024 Annual General Meeting

Dec 18, 2024, 8:00 PM EST - 8 months ago

InMed Announces Results of 2024 Annual General Meeting

InMed Enters Into Standby Equity Purchase Agreement

Dec 17, 2024, 4:56 PM EST - 8 months ago

InMed Enters Into Standby Equity Purchase Agreement

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 19, 2024, 7:30 AM EST - 9 months ago

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 14, 2024, 4:45 PM EST - 9 months ago

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 8, 2024, 4:44 PM EST - 10 months ago

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Nov 5, 2024, 8:30 AM EST - 10 months ago

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

Oct 28, 2024, 7:30 AM EDT - 10 months ago

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

Oct 24, 2024, 8:00 AM EDT - 10 months ago

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

Oct 22, 2024, 8:00 AM EDT - 10 months ago

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 30, 2024, 8:00 AM EDT - 11 months ago

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Sep 20, 2024, 4:30 PM EDT - 11 months ago

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Aug 21, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

Aug 20, 2024, 10:10 AM EDT - 1 year ago

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

Aug 20, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Jul 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

InMed to Present at the Emerging Growth Conference

Jun 10, 2024, 5:18 PM EDT - 1 year ago

InMed to Present at the Emerging Growth Conference

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 14, 2024, 8:30 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Apr 18, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Apr 16, 2024, 8:00 AM EDT - 1 year ago

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Apr 4, 2024, 8:00 AM EDT - 1 year ago

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Mar 20, 2024, 8:30 AM EDT - 1 year ago

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Feb 13, 2024, 5:41 PM EST - 1 year ago

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Feb 9, 2024, 8:00 AM EST - 1 year ago

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Jan 18, 2024, 4:41 PM EST - 1 year ago

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Jan 16, 2024, 8:00 AM EST - 1 year ago

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

InMed Announces Results of 2023 Annual General Meeting

Dec 19, 2023, 6:03 PM EST - 1 year ago

InMed Announces Results of 2023 Annual General Meeting

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

Nov 14, 2023, 8:04 AM EST - 1 year ago

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

Nov 2, 2023, 8:00 AM EDT - 1 year ago

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 7:15 PM EDT - 1 year ago

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

Oct 24, 2023, 4:38 PM EDT - 1 year ago

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

Oct 24, 2023, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

Sep 29, 2023, 1:21 PM EDT - 2 years ago

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

Sep 22, 2023, 6:15 PM EDT - 2 years ago

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 8:30 AM EDT - 2 years ago

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

Jul 21, 2023, 7:30 AM EDT - 2 years ago

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

InMed Provides Update on BayMedica Rare Cannabinoid Business

Jul 20, 2023, 7:30 AM EDT - 2 years ago

InMed Provides Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

Jun 22, 2023, 7:30 AM EDT - 2 years ago

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

Jun 1, 2023, 7:30 AM EDT - 2 years ago

InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

May 18, 2023, 5:00 PM EDT - 2 years ago

InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

May 15, 2023, 12:33 PM EDT - 2 years ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

MdcRaven13
MdcRaven13 Aug. 18 at 2:06 PM
$INM I imagine this one will heat up the higher that tilray and sundial go
0 · Reply
KKEE122
KKEE122 Aug. 18 at 3:09 AM
$INM According to my reading of the chart, I see that it is ready to launch $5 or more. I have informed you. Do not say that I have not informed you.
0 · Reply
SmartBetting
SmartBetting Aug. 14 at 2:20 PM
$INM showtime is coming. goodluck.
0 · Reply
Space0
Space0 Aug. 14 at 1:15 PM
$INM smart money vibes right here 🚀 He clearly sees the massive upside in $INM — and I’m with him on this one
0 · Reply
aw20
aw20 Aug. 11 at 9:55 AM
$INM when this one runs, it runs hard 👀 loaded the dip for the next good news
0 · Reply
Space0
Space0 Aug. 11 at 9:07 AM
$INM unusual strength without headlines — the tape might be telling us that good news is just around the corner
0 · Reply
SuperFugazi
SuperFugazi Aug. 11 at 6:51 AM
$INM idiot
0 · Reply
Lolonaktie
Lolonaktie Aug. 7 at 8:53 AM
$INM It's at rock bottom. We need to push the stock up.
0 · Reply
aw20
aw20 Aug. 6 at 3:20 PM
$INM loaded again at 2.27. Expecting news soon 👀 NFA
0 · Reply
april1688
april1688 Aug. 6 at 1:41 PM
$INM how is inm now?
0 · Reply
Space0
Space0 Aug. 5 at 9:10 PM
$INM i think something good is going to happen 👀
0 · Reply
marketk
marketk Aug. 5 at 2:44 AM
$INM
0 · Reply
Space0
Space0 Aug. 4 at 3:33 PM
$INM Wouldn’t be surprised if the INM poster’s tied to a broader announcement. Standard PR/internal review lag before public release. Worth watching
0 · Reply
Nizou
Nizou Aug. 1 at 2:49 PM
$INM
0 · Reply
Smilkky
Smilkky Jul. 31 at 7:55 PM
$INM AH boom, bought in a starter.
0 · Reply
aw20
aw20 Jul. 31 at 6:43 PM
$INM loaded more here at 2.38
0 · Reply
Bulltrader988
Bulltrader988 Jul. 31 at 6:25 PM
$INM 👃👀
0 · Reply
DetectingRunners
DetectingRunners Jul. 31 at 5:43 PM
$INM when news
0 · Reply
Space0
Space0 Jul. 31 at 4:19 PM
$INM the poster is expected to be published today or by tomorrow at the latest. It highlights compelling preclinical results — the kind that simply wouldn’t make it to a global stage unless they carried significant scientific value
0 · Reply
marketk
marketk Jul. 31 at 3:20 PM
$INM
0 · Reply
jerchess
jerchess Jul. 30 at 9:20 PM
$INM well fill the gap soon https://www.youtube.com/live/gb8sw9Q613Y?si=Y_gHvtIU_hzzx_wt
1 · Reply
DougAfter60
DougAfter60 Jul. 30 at 1:48 PM
$INM
0 · Reply